血浆肾素活性指导降压药物选择的效果

注册号:

Registration number:

ChiCTR-IOR-17012332 

最近更新日期:

Date of Last Refreshed on:

2017-08-10 21:42:00 

注册时间:

Date of Registration:

2017-08-10 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

血浆肾素活性指导降压药物选择的效果

Public title:

The effect of plasma renin activity on the selection of antihypertensive drugs

注册题目简写:

English Acronym:

研究课题的正式科学名称:

血浆肾素活性指导降压药物选择的效果

Scientific title:

The effect of plasma renin activity on the selection of antihypertensive drugs

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

贾志 

研究负责人:

贾志 

Applicant:

Jia Zhi 

Study leader:

Jia Zhi 

申请注册联系人电话:

Applicant telephone:

+86 13920323195

研究负责人电话:

Study leader's
telephone:

+86 13920323195

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

johnbikzly@163.com

研究负责人电子邮件:

Study leader's E-mail:

johnbikzly@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

天津市北辰区北医道7号

研究负责人通讯地址:

天津市北辰区北医道7号

Applicant address:

7 Beiyi Street, Beichen District, Tianjin, China

Study leader's address:

7 Beiyi Street, Beichen District, Tianjin, China

申请注册联系人邮政编码:

Applicant postcode:

300400

研究负责人邮政编码:

Study leader's postcode:

300400

申请人所在单位:

天津市北辰医院

Applicant's institution:

Tianjin Beichen Hospital

研究负责人所在单位:

天津市北辰医院

Affiliation of the Leader:

Tianjin Beichen Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

BCYYLL20170809

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

天津市北辰医院伦理委员会

Name of the ethic committee:

The ethic committee of Tianjin Beichen Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

1990-01-01 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

天津市北辰医院

Primary sponsor:

Tianjin Beichen Hospital

研究实施负责(组长)单位地址:

天津市北辰区北医道7号

Primary sponsor's address:

7 Beiyi Street, Beichen District, Tianjin, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

天津

市(区县):

Country:

China

Province:

Tianjin

City:

单位(医院):

天津市北辰医院

具体地址:

天津市北辰区北医道7号

Institution
hospital:

Tianjin Beichen Hospital

Address:

7 Beiyi Street, Beichen District, Tianjin, China

经费或物资来源:

自筹

Source(s) of funding:

Self financing

研究疾病:

难治性高血压  

Target disease:

Resistant hypertension

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

评价血浆肾素活性指导降压药物选择的治疗效果和预后  

Objectives of Study:

To evaluate the effect of plasma renin activity on the selection of antihypertensive drugs for resistant hypertension

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1、严重肝、肾疾病(GFR<30ml/1.73m2和ALT正常值上限2.5倍者);2、 孕妇、哺乳期妇女或有妊娠意向者;3、 肿瘤; 4、继发性高血压;5、不能坚持随访或依从性较差者。

Exclusion criteria:

1.Severe liver and kidney disease;
2. The pregnent woman;
3. Patients who have previous cancer treatments;
4. The secondary hypertension;
5. The poor compliance

研究实施时间:

Study execute time:

From 2017-09-01 00:00:00 To 2020-08-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2017-09-01 00:00:00 To 2019-08-31 00:00:00

干预措施:

Interventions:

组别:

对照组

样本量:

150

Group:

Control Group

Sample size:

干预措施:

传统方法选药

干预措施代码:

Intervention:

traditional method of drug selection

Intervention code:

组别:

研究组

样本量:

150

Group:

Research Group

Sample size:

干预措施:

新方法选药

干预措施代码:

Intervention:

New method of drug selection

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

天津 

市(区县):

 

Country:

China

Province:

Tianjin

City:

单位(医院):

天津市北辰医院 

单位级别:

三级 

Institution
hospital:

Tianjin Beichen Hospital

Level of the institution:

Tertiary A hospital

测量指标:

Outcomes:

指标中文名:

血压达标率

指标类型:

主要指标

Outcome:

the compliance rate of blood pressure

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

主要不良事件

指标类型:

次要指标

Outcome:

Major adverse events

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 75 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

SAS软件产生数字序列

Randomization Procedure (please state who generates the random number sequence and by what method):

Using the statistical analysis system

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

网络平台ResMan

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

IPD will be public accessable via ResMan

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

EXCEL表格

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

recorded on the EXCEL form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2017-08-10 21:42:00